Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, showing continued clinically and meaningful benefit for early Alzheimer’s disease patients.

ATTENTION-AD (ANAVEX 2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference.

Continued blarcamesine treatment for up to four (4) years demonstrated a good comparative safety profile and no associated neuroimaging adverse events (no potentially fatal brain bleeding or brain swelling).

There were no deaths related to the study drug.

Blarcamesine-treated patients continue to accrue benefit through 4 years, as measured by the clinical endpoints ADAS-Cog13 and ADCS-ADL.

Also Read: Neurodegenerative Disease-Focused Anavex Life Sciences’ Alzheimer’s Candidate Slows Disease Progression By Almost 39%

The delayed-start analysis for ADAS-Cog13 (assess cognitive function) showed a significant difference between the early start and late start treatment groups up to Week 192 (LS mean difference -3.83, P = 0.0165), favoring the early start group.

The results suggest that participants who initiated treatment with blarcamesine earlier in their disease progression showed greater cognitive function stability than those who did not initiate blarcamesine until ~1 year later.

In addition, an ADAS-Cog13 score difference between the treatment groups at Week 192 of more than 2 points is considered a clinically meaningful improvement.

Similarly, the delayed-start analysis for ADCS-ADL (functional evaluation scale) showed numerically favorable results for the early-start group over the late-start group up to Week 192. It reached statistical significance (LS mean difference +4.30, P = 0.0206).

With few or no interrupted treatment days, blarcamesine treatment resulted in an improved treatment effect for both cognition, ADAS-Cog13 (LS mean difference -4.20, P = 0.0083), and function, ADCS-ADL (LS mean difference +5.75, P = 0.0015) at Week 192.

Blarcamesine exhibited a favorable safety profile with the majority of adverse events (AEs) mild to moderate in severity (Grade 1 or 2), were predominantly linked to the initial titration phase, and could be managed with adjusted titration schedules.

Lastly, there are currently 74 participants receiving blarcamesine within the Compassionate Use Program, who continued treatment with blarcamesine subsequent completion of respective preceding open-label-extension studies from both ANAVEX 2-73-AD-EP-004 in early AD and from ANAVEX2-73-003 in mild-to-moderate AD.

Price Action: AVXL stock is down 1.71% at $8.05 at the last check Monday.

Read Next:

• Arvinas Potential Parkinson’s Treatment Shows Positive Data In Human Study

Photo by Berit Kessler via Shutterstock